Observational Study With InnoLet® in Daily Clinical Practice

Novo Nordisk

Status: Completed

Conditions: Diabetes Mellitus, Type 1; Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: insulin human

Study type: Observational

Funder types: Industry

Identifiers

NCT01492959

INNOLET-1888

Details and patient eligibility

About

This study is conducted in Asia. The aim of this study is to review the efficacy and safety of insulin treatment with InnoLet® in daily clinical practice.

Enrollment: 1,030 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Diabetes mellitus (Type 1 or type 2)
• Need insulin treatment

Trial design

1,030 participants in 1 patient group

Insulin human

Treatment:

Drug: insulin human